View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 4, 2021updated 11 Jul 2022 2:47pm

Janssen’s RSV vaccine meets all endpoints in Phase IIb trial in adults

The investigational vaccine demonstrated 70% efficacy against any symptomatic RSV-linked ARI and 80% efficacy against LRTD.

The Janssen Pharmaceutical Companies of Johnson & Johnson has reported that its experimental vaccine candidate for respiratory syncytial virus (RSV) met all endpoints in the Phase IIb CYPRESS clinical trial in adult subjects aged 65 and above.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The vaccine showed an 80% efficacy against RSV-caused lower respiratory tract disease (LRTD) in elderly patients in the trial.

The randomised, placebo-controlled, double-blind Phase IIb trial recruited a total of 5,782 subjects at 40 centres in the US.

These subjects were categorised into a 1:1 ratio before the onset of RSV season and given the vaccine or placebo.

Immunogenicity and safety evaluations were carried out in a subset of nearly 200 and 695 subjects, respectively.

A questionnaire or a clinician’s assessment helped to gather symptoms related to the disease.

The first incidence of RSV-caused LRTD was the primary goal while the secondary efficacy goal was the first manifestation of acute respiratory infection (ARI) linked to RSV.

Data also showed that the trial met primary and secondary goals, with the vaccine showing 70% efficacy against any symptomatic ARI linked to RSV.

In elderly subjects, the vaccine induced strong humoral and cellular immune responses, with those in the immunogenicity subset demonstrating a considerable improvement in RSV neutralising antibodies following 14 days of inoculation.

The vaccine was found to be well-tolerated in all subjects.

Janssen Research and Development Vaccines global therapeutic area head Penny Heaton said: “The findings from our CYPRESS study are very encouraging as we seek to deliver a long-awaited preventive vaccine to stave off the severe complications associated with RSV in adults.

“As older adults are at high risk of developing serious, a potentially life-threatening illness from RSV, there is an urgent need for a vaccine to prevent the significant morbidity and mortality caused by the virus.”

A common and extremely contagious respiratory virus, RSV causes bronchitis, bronchiolitis and pneumonia.

Last month, Janssen commenced the Phase III EVERGREEN trial of the vaccine in adult subjects aged 60 and above.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena